Market News & Trends
CROs Offer Promise of Innovative, Safe & Effective Development
Pharmaceutical and biotech companies are outsourcing research in order to develop innovative products that meet the rising demand for therapeutics across a range of…
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs
Biotech venture capital isn't what it used to be, but there's still money to invest in healthcare. Now one biotech investment firm just starting…
Generic Statins to Slash Global Market Value
The introduction of generic statins has kick-started a decline that will see the global statins market lose more than $7 billion in revenue by 2018,…
Patheon Makes Investment to Expand Early Development Capabilities
Patheon Inc. recently announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, UK, Milton Park is a dedicated pharmaceutical development…
Tapemark Expands Transdermal Patch Capabilities
Tapemark recently announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process.…
IBM Creating Superbug Busting Gel
Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research recently unveiled the first-ever antimicrobial hydrogel that can break apart biofilms and…
Idenix Announces Collaboration With Janssen
Idenix Pharmaceuticals, Inc. recently announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. for the clinical development of all-oral direct-acting antiviral (DAA) HCV combination therapies.…
LABLABO Inaugurates New Production Site
Based since 1971 close to Annemasse, France, LABLABO, a world leader in airless metering dispensers, has recently announced the celebrated the opening of its…
Threshold Pharmaceuticals Earns $30-Million Milestone Payment
Threshold Pharmaceuticals, Inc. recently announced that its partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase III MAESTRO study…
1/30/2013
Baxter International Makes $700-Million Acquisition Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter…
Baxter International Makes $700-Million Acquisition
Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter International. Baxter will acquire worldwide…
Biotrial Coming to US, Creating Hundreds of New Jobs
A French pharmaceutical research corporation that had been considering sites in New York and Boston to build its North American headquarters will soon break…
1/23/2012
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.…
Amgen Invests $200 Million in Monoclonal Antibodies
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.…
Domain Therapeutics Grants Prexton Therapeutics Exclusive License & Development Option
Domain Therapeutics S.A. recently announced that Domain Therapeutics granted Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive…
Imaxio Acquires Orphan Drug From D&A Pharma
Imaxio recently announced the acquisition of Trolovol (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. This…
MonoSol Rx Enters Licensing Agreement With Vestiq Pharmaceuticals
MonoSol Rx recently announced it has licensed Zuplenz (ondansetron) to Vestiq Pharmaceuticals, a specialty pharmaceutical company focused on innovative therapeutic remedies within the supportive…
The Quadruple Helix in the Human Genome Could Lead to New Cancer Drugs
The discovery of a quadruple helix in human cells could be a key to fighting cancer, according to the Cambridge researchers who made the…
Xceleron & Crystal Pharmatech Announce Strategic Development Partnership
Xceleron recently announced a partnership that will offer drug developers early bioavailability data that will lead to optimized solid-state forms and formulations. The partnership…
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio
Novozymes Biopharma recently announced the introduction of a new brand and visual identity for its recombinant human albumin (rAlbumin) portfolio. As part of the…
